贝伐珠单抗靶向治疗联合FOLFOX6化疗治疗直肠癌的效果及其对患者免疫功能的影响  

Efficacy of bevacizumab targeted therapy combined with FOLFOX6 chemotherapy in the treatment of rectal cancer and its effect on immune function in patients

作　　者：邹彬 Zou Bin(Changsha Central Hospital Affiliated to Nanhua University,Changsha,Hunan 410004,China)

机构地区：[1]南华大学附属长沙中心医院,湖南长沙410004

出　　处：《首都食品与医药》2024年第10期51-53,共3页Capital Food Medicine

摘　　要：目的研究分析贝伐珠单抗靶向治疗联合FOLFOX6化疗治疗直肠癌的效果及其对患者免疫功能的影响。方法选取南华大学附属长沙中心医院在2022年1月-2023年6月期间收治的72例直肠癌患者以随机抽签法分为观察组(n=36,采取贝伐珠单抗靶向治疗联合FOLFOX6化疗)和对照组(n=36,采取FOLFOX6化疗)。对比两组的临床疗效。结果两组治疗前的血清CEA、CA199、IGF-1、VEGF、CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比较,无明显差异(P>0.05),治疗后的上述指标均发生变化,观察组治疗后的CEA、CA199、IGF-1、VEGF、CD8^(+)均要低于对照组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)则要高于对照组(P<0.05);观察组的治疗总有效率高于对照组(P<0.05);两组的不良反应总发生率比较,无明显差异(P>0.05)。结论与单一FOLFOX6化疗治疗相比较,联合贝伐珠单抗靶向治疗直肠癌有着更加确切的疗效,能够降低肿瘤标志物与生长因子水平,改善机体治疗期间的免疫功能,且具有较高的安全性。Objective To study and analyze the efficacy of bevacizumab targeted therapy combined with FOLFOX6 chemotherapy in the treatment of rectal cancer and its influence on the immune function of patients.Methods 72 patients with rectal cancer admitted to our hospital from January 2022 to June 2023 were divided into observation group(n=36,bevacizumab targeted therapy combined with FOLFOX6 chemotherapy)and control group(n=36,FOLFOX6 chemotherapy)by random drawing method.The clinical efficacy of the two groups was compared.Result There was no difference in serum CEA,CA199,IGF-1,VEGF,CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)between the two groups before treatment(P>0.05),and the above indexes changed after treatment.After treatment,CEA,CA199,IGF-1,VEGF and CD8^(+)in observation group were lower than those in control group,while CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higher than those in control group(P<0.05).The total effective rate of observation group was higher than that of control group(P<0.05).There was no difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with FOLFOX6 chemotherapy alone,combined with bevacizumab has more accurate efficacy in the treatment of rectal cancer,can reduce the level of tumor markers and growth factors,improve the immune function during treatment,and has a high safety.

关 键 词：贝伐珠单抗 靶向治疗 FOLFOX6化疗 直肠癌 免疫功能 

分 类 号：R735.37[医药卫生—肿瘤]